

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 August 2005 (25.08.2005)

PCT

(10) International Publication Number
WO 2005/076975 A2

(51) International Patent Classification: **Not classified**

(21) International Application Number:
PCT/US2005/003754

(22) International Filing Date: 4 February 2005 (04.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/542,371 6 February 2004 (06.02.2004) US

(71) Applicant (for all designated States except US): **MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH** [US/US]; 200 First Street S. W., Rochester, MN 55905 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WETTSTEIN, Peter, J.** [US/US]; 508 8th Avenue SW, Rochester, MN



55902 (US). **STRAUSBAUCH, Mike** [US/US]; 4404 8th Street N.W., Rochester, MN 55901 (US). **HARDIN, Heather** [US/US]; 724 18th Avenue NE, Rochester, MN 55906 (US). **BORSON, Nancy** [US/US]; 415 15th Avenue NE, Rochester, MN 55906 (US).

(74) Agent: **ELLINGER, Mark, S.**; Fish & Richardson P.C., P.A., 60 South Sixth Street, Suite 3300, Minneapolis, MN 55402-1104 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: COMPLEXED POLYPEPTIDE AND ADJUVANT FOR IMPROVED VACCINES



(57) Abstract: Attachment of the strongly immunogenic polypeptide to a more weakly immunogenic polypeptide can precipitate and focus a CpG adjuvant to increase *in vivo* priming of a cytotoxic T-lymphocyte (CTL) response, and thus increase the immunogenicity of the more weakly immunogenic polypeptide. Accordingly, compositions that include a bipartite immunogenic polypeptide are provided herein. The bipartite polypeptide can include a CpG-interacting amino acid sequence fused to a CTL-activating amino acid sequence that can be heterologous to the CpG-interacting amino acid sequence. Also provided are methods of identifying and using a CpG-interacting amino acid sequence and a bipartite immunogenic polypeptide.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Complexed Polypeptide and Adjuvant for Improved Vaccines

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/542,371, filed February 6, 2004, which is incorporated herein by reference in its entirety.

5

GOVERNMENT SUPPORT

The work described herein was carried out, at least in part, using funds from the U.S. government under grant number AI-16052 awarded by THE NATIONAL INSTITUTES OF HEALTH. The government may therefore have certain rights in the invention.

TECHNICAL FIELD

10

This invention relates generally to the field of immunotherapy, and more particularly to enhanced immunogenic polypeptides.

BACKGROUND

15

Tumor-specific cytotoxic T-lymphocytes (CTLs) have been a principal focus for immunotherapy because of their exquisite specificity in lysing tumor cells with limited collateral damage. The objective of such immunotherapy is the priming for expansion of CTLs that are specific for tumor-specific polypeptides.

20

Proteins encoded by genes mapping to the major histocompatibility complex (MHC) present short polypeptides to cytotoxic and helper T cells. These short polypeptides provide the stimulus for activation and expansion of specific T cells. There has been a major focus on using these immunogenic polypeptides to vaccinate individuals for protection against infectious agents and tumors. The principal focus has been on polypeptides that are presented by MHC class I molecules to cytotoxic T lymphocytes (CTLs). In the case of human cancers, these polypeptides are usually injected in an oil emulsion along with cytokines and adjuvants. Importantly, the polypeptides that are used are generally of lengths that optimally bind to MHC class I molecules.

25

SUMMARY

The invention is based, at least in part, on the discovery that a short, strongly immunogenic polypeptide attached to a more weakly immunogenic polypeptide can complement the CpG adjuvant to increase *in vivo* priming of a cytotoxic T-lymphocyte (CTL)

response, and thus increase the immunogenicity of the more weakly immunogenic polypeptide. The strongly immunogenic polypeptide (referred to herein as a "CpG-interacting amino acid sequence") can include at least one cysteine (Cys) residue and, optionally, at least one positively charged amino acid residue. Furthermore, the CpG molecule can include at least one sulfur atom, such as in a phosphorothioate diester linkage. Accordingly, the invention provides compositions, including a bipartite immunogenic polypeptide that includes a CpG-interacting amino acid sequence fused to a CTL-activating amino acid sequence that can be heterologous to the CpG-interacting amino acid sequence. Also provided are methods of identifying and using a CpG-interacting amino acid sequence and a bipartite immunogenic polypeptide, such as for enhanced immunogenicity.

In one aspect, a composition containing a polypeptide and a CpG molecule is provided. The polypeptide can include (1) an amino acid sequence that can activate a cytotoxic T lymphocyte (CTL) (referred to herein as a "CTL-activating sequence"), and (2) a CpG-interacting amino acid sequence that is heterologous to the CTL-activating sequence. The CpG-interacting amino acid sequence can include at least one cysteine residue and, optionally, at least one positively charged amino acid residue, and the CpG molecule can include at least one sulfur atom. The CpG-interacting amino acid sequence can include no more than about 15 (*e.g.*, 12, 10, 8, or 6) amino acid residues, and the amino acid sequence can include a B-X or X-B sequence, or a B-X-B sequence, where B is a positively charged amino acid residue and X is any amino acid residue. The B residue can be, for example, an arginine or lysine. In one embodiment, the CpG-interacting amino acid sequence can be B-X-B-X-B, B-X-X-B-X-B, B-X-X-B-X-X-B, and the like. Furthermore, the amino acid sequence can include at least one cysteine residue and at least one (*e.g.*, 2, 3, 4 or more) positively charged amino acid residues. For example, the positively charged amino acid residues can flank the Cys residue. In one embodiment, the CpG-interacting amino acid sequence includes the sequence KCSRNR (SEQ ID NO:1).

In some embodiments, the CpG-interacting polypeptide may contain a cysteine residue and no positively charged amino acids. The cysteine residue can facilitate the interaction with the CpG molecule to create a complex with enhanced immunogenicity. The CpG-interacting amino acid sequence can therefore include the sequence XCX, where C is cysteine, and X is any amino acid. For example, in one embodiment, the CpG-interacting amino acid sequence includes the sequence ACSANA (SEQ ID NO:2).

In one embodiment, the CTL-activating amino acid sequence is not longer than about 50, amino acid residues (*e.g.*, about 25, 20, 15, or 10 amino acids, or less), and in another

embodiment the entire polypeptide (CTL-activating sequence + CpG-interacting amino acid sequence) is less than 50 amino acid residues (*e.g.*, about 40, 35, 30, 25, or 20 amino acids, or less) in length.

In one embodiment, the CpG molecule of a composition has a phosphorothioate
5 backbone.

Also provided herein are methods for producing a composition that has enhanced immunogenicity. One exemplary method includes (a) obtaining a polypeptide that has a CTL-activating sequence and a CpG-interacting amino acid sequence, and (b) contacting the polypeptide to a CpG molecule containing a sulfur atom. The CTL-activating amino acid
10 sequence can be heterologous to the CpG-interacting amino acid sequence, and the CpG-interacting amino acid sequence can include at least one cysteine residue and, optionally, at least one positively charged amino acid residue.

Also provided is a solution, such as an aqueous solution, that contains a precipitate. A “precipitate,” as referred to herein, is a solid material visible by the naked eye or by light
15 microscopy. A precipitate of a solution can contain a polypeptide, and a CpG molecule. As described above, the polypeptide can include a CTL-activating sequence and a CpG-interacting amino acid sequence. The CpG-interacting amino acid sequence can include at least one cysteine residue and, optionally, at least one positively charged amino acid, and the CpG molecule can include a sulfur atom.

The methods provided herein also include a method for making a solution. One such
20 method includes obtaining a polypeptide having a CTL-activating sequence and a CpG-interacting amino acid sequence, and contacting the polypeptide to a CpG molecule containing at least one sulfur atom. The contacting step can be performed in a solution, such as an aqueous solution, and under conditions favorable for precipitate formation between the
25 polypeptide and the CpG molecule. The CTL-activating sequence can be heterologous to the CpG-interacting amino acid sequence, and the CpG-interacting amino acid sequence can include at least one cysteine residue and at least one positively charged amino acid residue.

Methods for activating cytotoxic T lymphocytes are also provided. For example, one method for activating cytotoxic T lymphocytes in a mammal includes administering a
30 composition having a polypeptide and a CpG molecule to a mammal. As described above, the polypeptide can include a CTL-activating sequence and a CpG-interacting amino acid sequence that is heterologous to the CTL-activating sequence. The CpG-interacting amino acid sequence can include at least one cysteine residue and, optionally, at least one positively charged amino acid residue, and the CpG molecule can include at least one sulfur atom.

Screening methods are also provided. One such screening method includes a means of identifying a polypeptide that activates cytotoxic T lymphocytes. The method includes (a) combining a test polypeptide with a CpG molecule to form a mixture; (b) administering the mixture to a mammal, such as a mouse or a rat; (c) harvesting cytotoxic T lymphocytes from the mammal, such as from the spleen or lymph nodes of the mammal; and (d) determining whether or not the level of CD8⁺ cytotoxic T lymphocytes in the mammal is increased compared to the level of CD8⁺ cytotoxic T lymphocytes in the mammal before step (b). An increase in the level of CD8⁺ cytotoxic T lymphocytes indicates that the test polypeptide can activate cytotoxic T lymphocytes.

Another screening method can be used to identify a CpG-interacting amino acid sequence. According to one such method, a test amino acid sequence is contacted (*e.g.*, in solution) with a CpG molecule, and it is determined whether or not the test amino acid sequence and the CpG molecule can form a precipitate. The formation of a precipitate can indicate that the test amino acid sequence is a CpG-interacting amino acid sequence. The determination step can be performed, for example, by direct visualization, such as by looking for the formation of a precipitate in the solution. The determination step can also be performed by measuring the absorbance of the solution, such as comparing absorbance of the solution before and after the contacting step. A polypeptide that will form a precipitate with a CpG molecule is a candidate polypeptide that may be further tested for an ability to activate cytotoxic T lymphocytes. However, a polypeptide that does not precipitate a CpG molecule is not necessarily incapable of activating cytotoxic T lymphocytes, particularly if the polypeptide includes a cysteine.

Also provided are methods for identifying a candidate CpG-interacting amino acid sequence. In one embodiment, the method includes (a) administering a polypeptide/CpG molecule mixture to a mammal, and (b) determining whether or not the mixture activates CTLs from the mammal to a level greater than the level of activation that occurs in a control mammal that received a control polypeptide/CpG molecule mixture. The polypeptide of the polypeptide/CpG molecule mixture can include a CTL-activating amino acid sequence and a test amino acid sequence; the polypeptide of the control polypeptide/CpG molecule mixture will lack the test amino acid sequence. Determining that the level of CTL activation is greater in the presence of the test amino acid sequence is an indication that the sequence may be a CpG-interacting amino acid sequence. The determining step can include an immunocytochemical technique, such as an ELISA or ELISPOT assay.

One feature of the invention is a composition comprising a CpG molecule and a polypeptide containing more than about four cysteines (and more than about two disulfide bonds) within a sequence of about 100 contiguous amino acids. The polypeptide can be an antigenic polypeptide, such as a synthetic or a natural antigenic polypeptide. As used herein, a “natural polypeptide” contains an amino acid sequence that is found *in vivo*, such as in a mammal (*e.g.*, a human).

There are many advantages to delivering a polypeptide (*e.g.*, a polypeptide having a CpG-interacting amino acid sequence and a CTL-activating sequence) and CpG molecules together in the form of a therapeutic regimen or vaccine. Delivery of the two molecules in one immunotherapeutic composition simplifies vaccination, and in addition, can provide each component protection from degradation and facilitate transport of the components into the cell. The relative ease of producing the vaccines described herein can reduce the time required to develop a vaccine to months or weeks or even days. The relative ease can also facilitate the custom design of vaccines for individual tumor types, or particular pathogenic diseases, for timely application.

Sequestering the CpG molecule in a complex can also prevent the development of toxic, systemic responses that are frequently observed when free synthetic CpG molecules are administered. Without wishing to be bound by theory, the complexes may provide for a “timed-release” of smaller units composed of antigen and CpG.

In another advantage, the complexing phenomenon can be used for targeting small molecules for intracellular delivery, such as for gene therapy applications.

The development of effective, polypeptide-based vaccines for a number of different types of human cancers has been pursued in order to take advantage of the selective expression of specific polypeptides in those tumors. These efforts have principally focused on the use of polypeptides with lengths that are optimal for direct presentation to effector T lymphocytes. The compositions described herein, including the vaccine polypeptides described herein can be optimized specifically for *in vivo* priming through consideration of the mechanisms that regulate presentation of polypeptides by professional antigen presenting cells (APCs) to effector T cells.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, useful methods and materials are described below. The materials, methods, and examples are illustrative only and not intended

to be limiting. Other features and advantages of the invention will be apparent from the accompanying drawings and description, and from the claims. The contents of all references, pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference. In case of conflict, the present specification, including definitions, will control.

DESCRIPTION OF DRAWINGS

FIG 1A is a graphical presentation of the frequencies of IFN γ -secreting CTLs specific for three minor H antigen peptides, H60, HY1, and HY2. Stimulators included syngeneic and allogeneic spleen cells.

FIG 1B is a graphical representation of the frequencies of IFN γ -secreting CTLs specific for three minor H antigen polypeptides, H60, HY1, and HY2. Stimulators included RMA/S cells pulsed with the respective target peptides at concentrations of 10nM.

FIG. 2 is a graphical presentation of the frequencies of IFN γ -secreting CTLs in response to different concentrations of the indicated antigen polypeptides (HY2, HY1, KCSRNR-HY1, and RKKRRQ-HY1) mixed with CpG.

FIG. 3A is a graphical presentation of the frequencies of IFN γ -secreting CTLs. Mice were primed with CpG mixed with HY1 and the indicated HY1 polypeptides. CD8⁺ CTLs were mixed in a primary IFN γ Elispot assay with syngeneic male and female spleen cell stimulators.

FIG. 3B is a graphical presentation of the frequencies of IFN γ -secreting CTLs. B6 female mice were primed with CpG mixed with HY1 and the indicated HY1 polypeptides. A polypeptide that included a Cys-containing amino and carboxy terminal tail was included. CD8⁺ CTLs were mixed in a primary IFN γ Elispot assay with B6 female spleen cells that were untreated or pulsed with 1 μ M HY1 peptide.

FIG. 4 is a graphical presentation of the frequencies of IFN γ -secreting CTLs, when the spleen cells from the B6 female responders described in FIG 3B were re-stimulated with B6 male stimulator cells in primary MLCs. CD8⁺ CTLs were enriched from the surviving cells and mixed in a secondary IFN γ Elispot assay with B6 male spleen cells, untreated B6 female spleen cells, and B6 female spleen cells pulsed with 1 μ M HY1 peptide.

FIG. 5A is a graphical presentation of the frequencies of IFN γ -secreting CTLs detected in primary IFN γ Elispot assays. B6 female mice were primed with CpG + peptide in titrated doses (100, 40, 10 μ g of each component) and spleen cells were harvested after 10d

for enrichment of CD8⁺ CTLs. CTLs were mixed in primary IFN γ Elispot assays with B6 male and female stimulators

FIG. 5B is a graphical presentation of the frequencies of IFN γ -secreting CTLs detected in primary IFN γ Elispot assays. B6 female mice were primed with CpG + peptide in titrated doses (100, 40, 10 μ g of each component) and spleen cells were harvested after 10d for enrichment of CD8⁺ CTLs. CTLs were mixed in primary IFN γ Elispot assays with B6 female stimulators that were untreated and pulsed with 10nM HY1 peptide.

FIG. 6A is a graphical presentation of the frequencies of IFN γ -secreting CTLs detected in primary IFN γ Elispot assays. B6 female mice were primed with CpG plus KCSRNR-HY1 and ACSANA-HY1 and spleens and draining lymph nodes were harvested at 15, 29, and 50 days. CD8⁺ CTLs were enriched and mixed in primary IFN γ Elispot assays with untreated B6 female spleen cells or B6 female cells pulsed with 10nM peptide. Filled and open bars correspond to draining lymph nodes and spleens, respectively. Frequencies of CTLs responding to untreated B6 female stimulators have been subtracted to yield the reported specific frequencies.

FIG. 6B is a graphical presentation of the frequencies of IFN γ -secreting CTLs detected in primary IFN γ Elispot assays. B6 female mice were primed with CpG plus KCSRNR-HY1 and ACSANA-HY1 and spleens and draining lymph nodes were harvested at 15, 29, and 50 days. CD8⁺ CTLs were enriched and mixed in primary IFN γ Elispot assays with untreated B6 female spleen cells or B6 female cells pulsed with 1 μ M HY1 peptide. Filled and open bars correspond to draining lymph nodes and spleens, respectively. Frequencies of CTLs responding to untreated B6 female stimulators have been subtracted to yield the reported specific frequencies.

FIG. 7 is an example of primary ELISPOT assay results. The elimination of MPL-AF adjuvant from the priming combination of KCSRNR-HY1 and CpG appeared to increase the efficiency of priming. The wells shown include 2.5×10^5 CD8⁺ CTLs as responders and RMA-S stimulators pulsed with HY1 polypeptide. The graph indicates frequency of activated CD8⁺ T cells in response to polypeptide stimulation.

FIG. 8 is an example of primary ELISPOT assay results. The linkage of KCSRNR CpG-interacting amino acid sequences to two melanoma CTL-activating polypeptides (AAGIGILTV (MelanA) and KTWQYWQV (gp100)) and the immunodominant influenza polypeptide (GILGFVFT) resulted in increased priming of HLA-A2 transgenics when mixed with CpG +MPL-AF in comparison to their respective native polypeptides. The wells shown

include 3×10^5 CD8⁺ CTLs as responders with T2 stimulators pulsed with polypeptide. The graph indicates frequency of activated CD8⁺ T cells in response to polypeptide stimulation.

FIG. 9 is a graphical representation of absorption data. Formation of a precipitate results in decreased absorbance. The data indicate that positively charged residues in the CpG-interacting amino acid sequences of HY1 mediate virtually complete precipitation of CpG with concentrations used for *in vivo* priming.

FIG. 10 is a graphical representation of absorbance values for supernatants following the precipitation of CpG from solution with HY1-tailed bipartite polypeptides. Precipitates were cleared from the supernatants, which were then diluted 1/100 for spectrometric analysis at 260nm.

FIG. 11A is an RP-HPLC trace of a mixture of AASANA-HY1 + S1-CpG, where S1-CpG contains a single phosphorothioate group. Mixtures were separated by RP-HPLC with a gradient of 0-95% acetonitrile in 0.1% trifluoroacetic acid over 75 min.

FIG. 11B is an RP-HPLC trace of a mixture of ACSANA-HY1 + native CpG.

Mixtures were separated by RP-HPLC as described in FIG. 10A.

FIG. 11C is an RP-HPLC trace of a mixture of ACSANA-HY1 + S1-CpG (see FIG. 10A). Mixtures were separated by RP-HPLC as described in FIG. 10A.

FIG. 11D is an RP-HPLC trace of a mixture of ACSANA-HY1 and S1-CpG (see FIG. 10A), where the mixture was reduced with 0.05M DTT immediately prior to separation by RP-HPLC. Mixtures were separated by RP-HPLC as described in FIG. 10A.

FIG. 11E is an RP-HPLC trace of a mixture of ACSANA-HY1 and S1-CpG (see FIG. 10A) that had been alkylated with 10mM iodoacetamide prior to mixing. Mixtures were separated by RP-HPLC as described in FIG. 10A.

FIG. 11F is an RP-HPLC trace of a mixture of ACSANA-HY1 and S1-CpG (see FIG. 10A). Mixtures were separated by RP-HPLC as described in FIG. 10A.

FIG. 12 is a graphical presentation of the percentage of doubly-stained Langerhans cells. B6 female mice (3/group) were anesthetized and injected in the footpads with Texas Red-conjugated CpG plus the HY1, KCSRNR-HY1, and ACSANA-HY1 peptides that had been conjugated with Alexa 488. The recipients were sacrificed after 24 hr, and the popliteal lymph nodes were dissociated. The frequencies of doubly stained cells were estimated by fluorescence microscopy.

DETAILED DESCRIPTION

The invention is based, at least in part, on the discovery that a short, strongly immunogenic polypeptide attached to a weakly immunogenic polypeptide (referred to herein as a "CTL-activating" polypeptide) can complement a CpG adjuvant to increase the *in vivo* priming of a cytotoxic T-lymphocyte (CTL) response. The strongly immunogenic polypeptide (referred to herein as a CpG-interacting polypeptide) includes at least one cysteine (Cys) residue and, optionally, at least one positively charged amino acid residue. In addition, the CpG molecule includes at least one sulfur atom. Fusion of the strongly immunogenic CpG-interacting polypeptide with a CTL-activating polypeptide can produce a bipartite polypeptide featured in the invention. The amino acid sequence of the CTL-activating polypeptide can be heterologous to the amino acid sequence of the CpG-interacting polypeptide. The resulting bipartite immunogenic polypeptide can also be called a "primotope."

The CTL-activating amino acid sequence of the bipartite immunogenic polypeptide can be a polypeptide that binds to MHC Class I molecules. Thus, the bipartite immunogenic polypeptide of the invention can also be known as a CTL-activating polypeptide with enhanced priming potential, or an MHC Class I binding polypeptide with enhanced priming potential. The enhanced priming potential comes from a short CpG-interacting amino acid sequence fused to the polypeptide that binds MHC class I molecules. The short amino acid sequence includes at least one Cys residue and, optionally, at least one (e.g., 2, 3, or more) positively charged amino acids. At least one positively charged amino acid of the CpG-interacting amino acid sequence can be Arg, Lys, or His. The total length of the CpG-interacting amino acid sequence can be less than about 20 amino acids long (e.g., less than about 15, 12, 10, 8, or 6 amino acids long).

A CpG-interacting amino acid sequence can be added to an antigen of interest in order to increase the immunogenicity of that antigen. The cysteine residues of the CpG-interacting polypeptide (and hence the antigen to which it is attached) can interact, e.g., covalently bond, with a CpG molecule. The CpG molecule is an immune system stimulant that elicits a strong cell-mediated immune response. These CpG molecules are routinely used as adjuvants in vaccine research, during which they are given in their free form (they are not routinely linked to any other molecules as described in this disclosure). However, CpG molecules are not currently approved for human use because their systemic administration triggers a toxic shock response (this is one problem that the current disclosure overcomes). The majority of CpG molecules used as adjuvants are synthesized using a phosphorothioate backbone in order

to make the oligonucleotides more stable and less sensitive to nucleases. The presence of the sulfur groups in the phosphorothioate backbone of the CpG oligonucleotides may allow for the formation of disulfide bonds with the sulfur residue of the cysteines contained in the CpG-interacting amino acid sequence. This disulfide covalent linkage between the CpG-interacting amino acid sequence and the CpG oligonucleotide may help facilitate the increased antigen immunogenicity.

The aggregation of several polypeptides-CpG compounds can form a precipitate and demonstrate increased antigen immunogenicity. The positively charged amino acids of the CpG-interacting amino acid sequence can interact with the negatively charged backbone of the CpG oligonucleotides to form the aggregates. The resulting precipitate can perform two functions: (1) it can increase aggregate (antigen) uptake by antigen presenting cells (the first step in forming an immune response to the antigen) and (2) it can localize the CpG molecules to prevent systemic circulation (and hence toxic shock). The CpG-interacting amino acid sequences can have a periodicity of positively charged amino acids. Because of the helical nature of one or more CpG molecules, the negative charges are oriented in a certain way. In order for the CpG-interacting amino acid sequence to orient the positively charged amino acids into a conformation best able to bind the negative charges of the CpG molecule, single or multiple spacer amino acids can be used. A general orientation can be B-X, or X-B, or B-X-B, where B is a positively charged amino acid residue, and X is an amino acid residue. The B residue can be, for example, an arginine or lysine or histidine. In one embodiment, the CpG-interacting amino acid sequence can be B-X-B-X-B, B-X-X-B-X-B, B-X-X-B-X-X-B, and the like.

In some cases, a CpG-interacting polypeptide may contain a cysteine residue and no positively charged amino acids. The cysteine residue can facilitate the interaction with the CpG molecule to create a complex with enhanced immunogenicity. The CpG-interacting amino acid sequence can therefore have the include the sequence XCX, where C is cysteine, and X is any amino acid.

The development of immunotherapeutic methods can provide alternative treatments for human tumors that resist standard treatment methods including chemotherapy and radiation therapy. Tumor-specific cytotoxic T lymphocytes (CTLs) have been a principal focus for immunotherapy because of their exquisite specificity in lysing tumor cells with limited collateral damage. The objective of such immunotherapy is the priming for expansion of CTLs that are specific for tumor-specific polypeptides presented by products of class I genes of the major histocompatibility complex.

Class I-binding polypeptides that include multiple positively charged amino acids and at least one cysteine residue exhibit the ability to complex with and precipitate CpG molecules, and the addition of these amino acids to weakly immunogenic polypeptides increases immunogenicity when combined with CpG molecules for immunization. This increased immunogenicity is accompanied by a decrease in the systemic effects of CpG molecules suggesting that co-precipitated polypeptide and CpG molecules provide the basis for development of vaccines with increased immunogenicity and half-life with reduced adjuvant-mediated toxicity. The simultaneous delivery of two components simplifies the administration of vaccine and expectedly provides protection from degradation for each component. The relative ease of production of these vaccines would enable custom designing of vaccines for individual tumor types for timely administration.

Bipartite Immunogenic Polypeptides The bipartite immunogenic polypeptides of the invention can consist of a CpG-interacting amino acid sequence (e.g., a CpG-interacting amino acid "tail") and a CTL-activating sequence, which can be heterologous to the CpG-interacting amino acid sequence. The CpG-interacting amino acid sequence can be located at any position in the bipartite immunogenic polypeptide, such as at, or near, the N- or C-terminus, or in about the middle of the polypeptide. The CTL-activating sequence can be an MHC Class I binding polypeptide. An immunogenic polypeptide of the invention is the shortest polypeptide that can be efficiently processed and presented by APCs, bound by class I molecules, and recognized by specific CTLs *in vivo*. The total length of the bipartite immunogenic polypeptide can be less than about 100 amino acids long, preferably less than about 50 amino acids long (e.g., less than about 40, 35, 30, 25, 20, or 15 amino acids long).

Fully processed polypeptides are those that optimally bind to MHC molecules for recognition by effector T cells. Without wishing to be bound by theory, the positively charged CpG-interacting amino acid sequence can provide the necessary characteristics that allow the immunogenic polypeptide of the invention to be taken up by APCs.

CpG-Interacting Amino Acid Sequence The CpG-interacting amino acid sequence can complex with and concentrate the adjuvant activity of CpG motifs for activation of localized APCs.

The CpG-interacting amino acid sequence can include 0, 1, 2, 3, or more positive amino acids. An excess of positively charged residues may block T cell activation and expansion in a short term scenario, but may be effective in stimulating T cell activation over a long term period (e.g., longer than 30, 40, 50, 75, 100, or 150 days, or longer). This inhibition may be caused by a concentrated precipitation of CpG that sequesters both the

polypeptide and CpG in an inactive complex. The Cys and positively charged amino acids can occur at any position within the CpG-interacting amino acid sequence, and the other amino acids can be any amino acid, but preferably positively charged amino acids are spaced at regular intervals throughout the sequence. For example, a positively charged amino acid
5 can be positioned at every other, every third, or every fourth amino acid position. It is not necessary that the placement of the positive amino acid residues has perfect periodicity. The CpG-interacting amino acid sequence can be, for example, any CpG-interacting amino acid sequence described herein. The CpG-interacting amino acid sequence can be, for example, KCSRNR or ACSANA.

10 While not wishing to be bound by theory, the cysteine residues of the CpG-interacting amino acid sequence can interact with, e.g., covalently link, the CpG-interacting amino acid sequence (and so also the CTL-activating amino acid sequence to which it is attached) to a CpG molecule.

CTL-Activating Amino Acid Sequence A "CTL-activating" polypeptide is defined by
15 a CTL-activating amino acid sequence. A polypeptide can be categorized as a CTL-activating polypeptide if administration to a mammal, such as a mouse, or a human, results in increased levels of activated CTLs. The level of activated CTLs can be monitored by a variety of methods known in the art, including, but not limited to, ELISA and ELISPOT assays.

20 Polypeptides that are rich in disulfide bonds (such as IgG) may not require a heterologous CpG-interacting sequence, but instead can themselves bind enough CpG molecules to elicit a heightened immune response. These highly antigenic polypeptides can have at least four cysteine residues (e.g., 5, 10, 15, 20, 25, or 30 cysteines) per 100 contiguous amino acids. The polypeptide can also be rich in disulfide bonds. For example,
25 the polypeptide can contain at least two disulfide bonds (e.g., 3, 4, 5, 6, 7, 8, 9, 10, or 15 disulfide bonds) when it is folded in its natural state. The antigenic polypeptide can be treated with a denaturant, such as urea, guanidine chloride, guanidine thiocyanate GdmSCN, or heat and beta-mercaptoethanol, to break the disulfide bonds, and then the denatured polypeptide can be mixed with CpG molecules and a precipitate allowed to form. The
30 resulting mixture can be used as an immunotherapeutic formulation as described herein.

CpG molecule A CpG molecule, as described herein, is an oligonucleotide that contains at least one unmethylated cytosine-guanine dinucleotide. CpG molecules can be about 15-25 nucleotides long, preferably about 18-20 nucleotides long. The oligonucleotide can include at least one CpG consensus motif of RRCpGYG (R is purine and Y is

pyrimidine). The CpG molecules can include a backbone of at least one phosphorothioate linkage, and preferably, the backbone of the entire CpG molecule consists of phosphorothioate linkages. The side chains of a phosphorothioate backbone contain at least one or more sulfur atoms in place of oxygen, and a phosphorothioate backbone can yield a longer half life, increased level of activity, and subtle changes in the specificity of activity (Kreig, *Annu. Rev. Immunol.* 20:709, 2002) compared to an oligonucleotide backbone that does not include a sulfur atom. While not being bound by theory, the sulfur atoms of the phosphorothioate backbone can form disulfide linkages with the Cys residue(s) of the CpG-interacting amino acid sequence, which can enhance the immunogenic response.

Any CpG molecule, or any DNA molecule with a phosphorothioate linkage for coupling through disulfide bonds, can be used in the compositions and methods described herein. For example, the CpG molecule 1826 (5'-TCC A TG ACG TTC CTG ACG TT-3'), specific for mouse TLR (Davis *et al. J. Immunol.* 160:870, 1998) can be used as described. See also CpG molecules described in Lingnau *et al. (Vaccine* 20:3498-3508, 2002), for example.

Immunotherapeutic Formulations The compositions and methods described herein can be used in the form of vaccinations, to treat or prevent a disease or disorder, such as cancer. An exemplary immunotherapeutic composition contains a bipartite immunogenic polypeptide and CpG molecules in an oil emulsion, such as Incomplete Freund's Adjuvant. Optionally, an immunotherapeutic composition can include MPL-AF (monophosphoryl Lipid A adjuvant (MPL) mixed with dipalmitoyl phosphatidyl choline (DPPC)).

An immunotherapeutic composition described herein can contain a heterologous mixture of bipartite immunogenic polypeptides. For example, the mixture can contain polypeptides with distinct CTL-activating and CpG-interacting amino acid sequences, or one species of CTL-activating sequences can be coupled to a variety of different CpG-interacting amino acid sequences. The use of various CpG-interacting amino acid sequences can provide a collection of bipartite immunogenic polypeptides with varying stability and varying CTL activation capabilities. For example, and without wishing to be bound by theory, shorter CpG-interacting amino acid sequences containing fewer or one cysteine residue can activate CTLs in the shorter term, providing an immediate priming effect, while longer CpG-interacting amino acid sequences with multiple cysteine residues, or greater numbers of positively charged residues, can provide longer-term priming activity.

As used herein, a vaccine is a composition that provides protection against a viral infection, cancer or other disorder or treatment for a viral infection, cancer or other disorder.

Protection against a viral infection, cancer or other disorder will either completely prevent infection or the tumor or other disorder, or will reduce the severity or duration of infection, tumor or other disorder if subsequently infected or afflicted with the disorder. Treatment will cause an amelioration in one or more symptoms or a decrease in severity or duration. For purposes herein, a vaccine results from administration of the bipartite immunogenic polypeptides and CpG molecules described herein. As used herein, amelioration of the symptoms of a particular disorder by administration of a particular composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.

Administration of the immunotherapeutic compositions described herein can activate Langerhans cells and antigen presenting cells (APCs), each of which is capable of presenting the antigenic polypeptide to CTLs, thereby activating the CTLs. The immunotherapeutic compositions can also be administered with a second therapeutic agent or regimen. For example, an immunotherapeutic agent can be administered to a patient who also receives chemotherapy or radiation therapy, such as for a cancer.

An immunotherapeutic composition described herein can be provided in solution, such as in sterile water or a buffer, or the composition can be packaged in a lyophilized form. Kits containing the compositions can include solubilizing reagents, such as sterile water or buffers and/or reagents for diluting a solution and/or otherwise adjusting the properties of a solution in preparation for an intended use. A kit can also include informational material; informational material can be descriptive, instructional, marketing or other material that relates to the methods described herein and/or the use of the immunotherapeutic compositions for the methods described herein.

The informational material of the kits is not limited in its form. In many cases, the informational material is provided in printed matter, such as in printed text, drawings, and/or photographs. The instructional material can be in the form of a label or printed sheet. However, the informational material can also be provided in other formats, such as Braille, computer readable material, video recording, or audio recording. The informational material can include contact information, such as a physical address, email address, website, or telephone number, where a user of the kit can obtain substantive information about an immunotherapeutic composition and/or its use in the methods described herein. Of course, the informational material can also be provided in any combination of formats.

The compositions can be packaged in a variety of suitable containers. For example, a composition can be contained in a bottle, vial, or syringe, composed of a material such as

glass or plastic. Optionally, the compositions can be packaged in individual dosage form, such as in ampoules, syringes, or blister packs. Containers can be air tight and/or waterproof, and can be labeled for use, such as for a vaccine, or to stimulate a CTL response, or to treat a cancer.

5 *Effective Dose* The compositions described herein can be administered on multiple occasions and at varying concentrations.

Toxicity and therapeutic efficacy of the compositions disclosed herein (*e.g.*, immunotherapeutic compositions) can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LD₅₀ (the dose lethal to
10 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD₅₀/ED₅₀. Polypeptides or other compounds that exhibit large therapeutic indices are preferred.

Data obtained from the cell culture assays and further animal studies can be used in
15 formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any composition used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A
20 dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (that is, the concentration of the immunogenic polypeptides and CpG molecules (free and complexed) which achieves a half-maximal inhibition of symptoms, *e.g.*, treatment of a tumor and/or CTL-activation) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. The amount of bipartite
25 immunogenic polypeptide and CpG molecule in a vaccine dose is selected as an amount that induces an immunoprotective response without significant, adverse side effects in a vaccinee. Such amount can vary depending on the target (*e.g.*, a tumor or systemic vaccination procedure). Generally it is expected that each dose will comprise less than about 500 μ g (*e.g.*, less than about 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 20 10, 5 or 1 μ g) each of total
30 bipartite immunogenic polypeptide and CpG molecule. The dose can, optionally, comprise an equal molar ratio of the two components. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of CTL responses, antibody titres, and other responses in subjects.

Following an initial vaccination, subjects may receive a boost in about 4 weeks. The formulations and routes of administration can be tailored to the specific disorder being treated, and for the specific human being treated. For example, the human can have a cancer, such as a leukemia, or a tumor, such as a tumor of the breast, colon, prostate, pancreas or lung.

Generally, administration of an immunotherapeutic agent facilitates an intended purpose for both prophylaxis and treatment without undesirable side effects, such as toxicity, irritation or allergic response. Although individual needs may vary, the determination of optimal ranges for effective amounts of formulations is within the skill of the art. Human doses can readily be extrapolated from animal studies (Katocs *et al.*, Chapter 27 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990). Generally, the dosage required to provide an effective amount of a formulation will vary depending on several factors, including the age, health, physical condition, weight, type and extent of the disease or disorder of the recipient, frequency of treatment, the nature of concurrent therapy, if required, and the nature and scope of the desired effect(s) (Nies *et al.*, Chapter 3, In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman *et al.*, eds., McGraw-Hill, New York, N.Y., 1996).

Screening Methods Various screening methods are also provided herein. One such screening method can be used to identify polypeptides that activate cytotoxic T lymphocytes. The CTL-activating polypeptides can be used in the production of the bipartite immunogenic agents described herein. The methods can include, for example, combining a test polypeptide with a CpG molecule, administering the mixture to a mammal, such as a mouse or a rat, harvesting cytotoxic T lymphocytes from the mammal, and determining whether or not the level of cytotoxic T lymphocytes (*e.g.*, CD8⁺ CTLs) in the mammal is increased.

Other screening methods include procedures to identify a CpG-interacting amino acid sequence, such as for use in a bipartite immunogenic polypeptide. For example, a test amino acid sequence can be contacted with a CpG molecule, and the mixture observed for the formation of a precipitate. The formation of a precipitate indicates that the test amino acid sequence is a CpG-interacting amino acid sequence. The method can further include administering a bipartite immunogenic polypeptide that contains the identified CpG-interacting amino acid sequence. The polypeptide can be administered to a mammal in a formulation with a CpG molecule. By determining whether the polypeptide/CpG molecule composition can activate CTLs in the mammal, it can be determined that the test CpG-

interacting amino acid sequence can function *in vivo* as part of an effective immunotherapeutic reagent.

Sequences identified as CTL-activating sequences or CpG-interacting amino acid sequences can be recorded in a print or machine-readable form. Further, polypeptides containing the identified sequences can be further tested in humans and assayed for an immunogenic response.

The invention is further illustrated by the following examples, which should not be construed as further limiting.

10

EXAMPLES

Example 1: An immunogenic polypeptide precipitates CpG and enhances activation of CTLs Early experiments in our lab focused on methods required to increase the T cell response to minor histocompatibility antigen (MiHA) polypeptides in mice. Over the past ten years, we have observed a continued decline in the ability of mice to generate CTLs specific for MiHA polypeptides. This decline may be due to the increasingly stringent husbandry procedures in our mouse rooms that have reduced the exposures to pathogens to the point where the immune systems of our mice have no reason to do anything more than maintain homeostasis. Since shifting to primary ELISPOT for quantitation of CTL that produce IFN γ upon stimulation, we have observed that background spots are virtually non-existent in our mice. This is in direct contrast to primary ELISPOT assays with human CTLs, where background activity is ever-present. These observations are consistent with overall decreases in immune activity that must be overcome for effective generation of CTL responses.

Since the defect appeared to be founded in limited exposure to pathogens, we explored the use of bacterial adjuvants to increase CTL responses to MiHA rather than the use of pharmacological methods, *e.g.*, antibody-mediated co-stimulation. We settled on the use of LipidA and a CpG molecule, that bind to TLR-4 and TLR-9, respectively, based on their reported abilities to enhance CTL responses. Lipid A was provided by Corixa Corporation (Seattle, WA) in the form of MPL-AF (MPL adjuvant (monophosphoryl Lipid A) mixed with surfactant-like dipalmitoyl phosphatidyl choline (DPPC)). The CpG molecule used was the 1826 oligonucleotide (TCCA TGAC GTTC CTGA CGTT) that is specific for mouse TLR-9 (Davis *et al.*, *J. Immunol.* 160:870, 1998.); the CpG oligonucleotides were synthesized by the Mayo Clinic Molecular Biology Core with a phosphorothioate backbone (unless otherwise specified, our use of the term CpG will refer to this synthetic form). In an

effort to avoid the intense, systemic inflammation previously observed in mice treated repeatedly with CpG, we mixed CpG, MPL, and antigen for use in single challenges. Preliminary experiments were performed with 10 μ g MPL-AF + 100 μ g CpG mixed with either MiHA-incompatible spleen cells or synthetic MiHA polypeptides (100 μ g) for sub cu
5 (s.c.) injection in the base of the tail.

Frequencies of IFN γ -secreting, MiHA-specific CTLs were estimated by the use of primary ELISPOT assays that utilized CD8⁺ responders that were enriched by negative selection of other lymphoid populations with MACS CD8⁺ Negative Selection Kits (Miltenyi Biotec, Auburn, CA).

10 The WMHHNMDLI (HY1) and KCSRNRQYL (HY2) peptides are derived from proteins encoded by murine Y-linked genes and are presented by H2D^b molecules to CTLs (King *et al.*, *Genomics* 24:159-168, 1994; Greenfield *et al.*, *Nat. Genetics* 14:474-478, 1996). Mixtures of these two peptides and combined MPL-AF plus CpG adjuvants were tested for their capacities to prime CTL responses. These two peptides were also compared for *in vivo*
15 priming efficiency with an immunodominant H60 peptide (LTFNYRNL) (Malarkannan *et al.*, *J. Immunol.* 161:3501-3509, 1998). B6 females were primed s.c. and spleens were harvested 10 days after immunization. CD8⁺ CTLs were enriched by negative selection and stimulated with (1) syngeneic female spleen cells, (2) syngeneic male spleen cells, (3) allogeneic (BALB.B) spleen cells for anti-H60 CTLs, and (4) peptide-pulsed RMA/S cells in
20 primary Elispot assays to estimate the frequencies of IFN γ -secreting CTLs. Primary Elispot assays were performed with CD8⁺ splenocyte responders from recipients of single immunizations with 100 μ g polypeptide plus 100 μ g CpG and 10 μ g MPL-AF. RMA/S cells were pulsed with the respective target polypeptides at concentrations of 10 nM. Responders and stimulators were cultured in anti-IFN γ capture antibody-coated ELISPOT plates
25 for 48 hr after which biotinylated anti-IFN γ detection antibodies were added followed by streptavidin-conjugated HRP and AEC substrate. Spots were counted by first obtaining digitized images of the wells (performed by C.T.L. Analyzers, Cleveland, OH) and then analyzing these images with Immunospot software purchased from C.T.L. Analyzers. On the basis of frequencies of responding CTLs, the HY2 polypeptide was the most efficient primer
30 of CTLs whereas the H60 polypeptide was the most inefficient (FIGs. 1A and 1B); see also U.S. Provisional Application No. 60/542,371.

The HY2 polypeptide was distinguished from the other test polypeptides (HY1, H60, and several others) by the formation of precipitates when MPL + CpG were mixed with HY2.

The precipitations only required HY2 and CpG (MPL was not required). The HY2 amino acid sequence was examined for characteristics that could promote increased immunogenicity and complexing with the CpG molecule. We tested a panel of polypeptides, some of which did not precipitate upon the addition of CpG, and found that if positively charged amino acids were added to these non-precipitating polypeptides, they now formed precipitates with CpG.

We hypothesized that (1) the formation of precipitates is due to ionic bonds between the positively charged residues in HY2 and the negative charges on CpG molecules and (2) this precipitation enhances stimulation of CTLs. To test these hypotheses, we synthesized two variants of HY1, in which KCSRNR- and RKKRRQ- sequences were added to the amino termini. The KCSRNR sequence was derived from HY2 and the RKKRRQ sequence was derived from the active HIV TAT polypeptide (keeping the length of the CpG-interacting amino acid sequence at six amino acids) (Vives *et al.*, *J. Biol. Chem.* 272:16010, 1997). The two bipartite polypeptides (but not native HY1) precipitated CpG, supporting our first hypothesis. When mixed and injected with CpG + MPL, the HY1 polypeptide fused to the KCSRNR amino acid sequence strikingly increased the frequency of HY1-specific CTLs (see FIG. 2).

With regard to the RKKRRQ-containing polypeptides, we have also observed that the complete, active HIV TAT polypeptide used in Trojan constructs (Lu *et al.*, *J. Immunol.* 166:7063, 2001) intensely precipitates CpG to the degree that it is difficult to inject, and it inhibits the initial adjuvant activity of CpG in short-term functional assays. Too many positive charges can block T cell activation and expansion. This is consistent with the observation that poly-Arg (60 residues) can rapidly precipitate CpG (Lingnau *et al.*, *Vaccine* 20:3498, 2002); such precipitates can be deposited in tissue and have very long life-spans *in vivo* as evidenced by the ability of these precipitates with associated immunogenic polypeptides to continue priming for at least 372 days (Lingnau *et al.*, *Vaccine* 20:3498, 2002). The potential for selectively and strongly precipitating both immunogenic polypeptides and CpG provides the means to stimulate long-term and durable CTL responses.

To test the CTL priming capability of the bipartite polypeptides, B6 females were primed with mixtures of CpG adjuvant and HY1, KCSRNR-HY1, RKKRRQ-HY1, and HY2. Spleens were harvested 10 days thereafter for enrichment of CD8⁺ CTLs for primary IFN γ Elispot assays with peptide-pulsed RMA/S cells as stimulators (FIG. 2). Consistent with the results reported in FIGs. 1A and 1B, HY2 primed for greater frequencies of CTLs than HY1 at all tested peptide concentrations. The linkage of the KCSRNR tail with the HY1 target peptide resulted in frequencies of HY1-specific CTLs that were comparable to those obtained

with HY2. The RKKRRQ tail increased priming efficiency to an intermediate level compared to HY1 versus KCSRNR-HY1. The HY2, KCSRNR-HY1, and RKKRRQ-HY1 peptides all precipitated CpG oligonucleotides. The increased priming efficiency of KCSRNR-HY1 indicated that the addition of this six amino acid sequence carrying three positively charged residues increased HY1-specific priming. However, the intermediate efficiency associated with the RKKRRQ-HY1 peptide with five positively charged residues suggested that increasing the number of positively charged amino acids was not associated with further increased priming.

10 *Example 2: A cysteine residue is important for increased immunogenicity.* To examine the role of Arg/Lys residues in the KCSRNR CpG-interacting amino acid sequence of the HY1 bipartite polypeptide, we substituted Ala residues for the three positively charged residues. The altered bipartite polypeptides were each mixed with CpG to prime B6 female mice. Spleen cells were harvested at day 10 and CD8⁺ CTLs were enriched for quantitation in primary and secondary IFN γ Elispot assays. As in prior experiments, priming with KCSRNR-HY1 resulted in higher frequencies of HY1-specific CTLs in primary Elispot assays than priming with the fully processed HY1 peptide (FIGs. 3A and 3B). This ranking was observed with both syngeneic male (FIG. 3A) and HY1-pulsed syngeneic female spleen cell stimulators (FIG. 3B). To our surprise, substitution of Ala for all Arg/Lys residues in the ACSANA-HY1 polypeptide did not result in the loss of priming efficiency although it did result in the loss of the ability to precipitate CpG. In fact, polypeptide-pulsed female cells stimulated higher frequencies of HY1-specific CTLs from mice primed with ACSANA-HY1 than with KCSRNR-HY1 (FIG. 3B). Confirmatory results were obtained in secondary Elispot assays of CTLs expanded by stimulation with syngeneic male spleen cells in primary MLCs (FIG. 4). Comparable frequencies of HY1-specific CTLs were stimulated with syngeneic male spleen cells and peptide-pulsed spleen cells when responder CTLs were derived from mice primed with KCSRNR-HY1 and ACSANA-HY1.

30 Synthetic CpG oligonucleotides are typically synthesized with phosphorothioate linkages to reduce susceptibility to nucleases *in vivo* (Stein *et al.*, *Nucl. Acids Res.* 16:3209-3221, 1988). One explanation for the pre-eminent role of Cys in driving *in vivo* priming is the formation of disulfide bonds between the Cys-containing HY1 primotopes and synthetic CpG oligonucleotides. The importance of the Cys residue for *in vivo* priming with the KCSRNR-HY1 and ACSANA-HY1 primotopes was confirmed by additional Ala substitutions. The KASRNR-HY1 primotope (Cys>Ala) exhibited virtually no priming

potential as evaluated by both primary and secondary Elispot assays (FIGs. 3A and 3B, and FIG. 4). However, the KASRNR-HY1 polypeptide still retained the capacity to visibly precipitate CpG. The AASANA-HY1 polypeptide was similar to KASRNR-HY1 in its lack of *in vivo* priming capacity. These results supported the hypothesis that the single Cys residue was required for optimal HY1-specific priming, potentially through the formation of disulfide bonds with the phosphorothioate linkages of synthetic CpG oligonucleotides. We investigated the possibility that additional Cys residues in the peptides would increase immunogenicity through the ability to cross-link multiple CpG molecules. An HY1 polypeptide was synthesized with amino and carboxy tails carrying single Cys residues: ACSANA-HY1-ANASCA. This polypeptide was combined with CpG for priming of B6 females with frequencies of HY1-specific CTLs estimated by primary and secondary Elispot assays. A significant increase in priming efficiency was observed relative to priming with the ACSANA-HY1 polypeptide as revealed by frequencies of HY1-specific CTLs that responded to syngeneic male stimulators in primary Elispot assays (FIG. 3A). Further, comparable frequencies of HY1-specific CTLs were observed in secondary Elispot assays of CD8⁺ CTLs from mice primed with all three polypeptides tailed with Cys residues, i.e., ACSANA, KCSRNR, and double ACSANA tails (FIG. 4).

Example 3. Increased priming efficiency is concentration dependent. We sought to determine if increased priming efficiency with ACSANA-HY1 could still be observed with reduced doses of bipartite polypeptide and CpG. B6 females were primed with mixtures of CpG plus HY1 and ACSANA-HY1 at doses of 100, 40, and 10 µg of each of the two components. Spleens were harvested 10 d later for enrichment of CD8⁺ CTLs for primary and secondary Elispot assays with syngeneic male and female spleen cell stimulators, the latter of which were either untreated or pulsed with HY1. In primary Elispot assays (FIGs. 5A and 5B), priming efficiency was maintained with 40 µg doses of ACSANA-HY1 peptide but not with the fully processed HY1 peptide when tested with syngeneic male stimulators (FIG. 5A) and female stimulators pulsed with 10 nM HY1 peptide (FIG. 5B). No priming was detectable in primary Elispot assays with 10 µg of either ACSANA-HY1 or HY1. Comparable results were obtained in secondary Elispot assays with syngeneic male stimulators and HY1-pulsed syngeneic female stimulators; in the case of HY1-pulsed stimulators, frequencies of CTLs primed with all doses of ACSANA-HY1 were significantly higher than those of CTLs primed with the corresponding doses of HY1.

Example 4. Efficiency of priming by bipartite polypeptides varies over time. We have observed that the presence of Arg/Lys residues in HY1 primotope tails promotes precipitation of CpG, and other investigators have observed that poly-Arg precipitates CpG oligonucleotides that remain deposited at injection sites for extended periods of time with associated extended priming of CTLs (Lingnau *et al.*, *Vaccine* 20:3498-3508, 2002). We hypothesized that such extended deposition would occur with KCSRNR-HY1 which would then prime for longer periods of time than ACSANA-HY1 that does not precipitate CpG oligonucleotides but strongly primes primary CTL responses. B6 females were primed with CpG plus KCSRNR-HY1 or ACSANA-HY1 and spleens and draining lymph nodes were harvested at 15, 29, and 50 days for primary Elispot assays with peptide-pulsed syngeneic female stimulators (FIGs. 6A and 6B). These results showed that ACSANA-HY1 was most efficient at priming CTLs in both spleen and draining lymph nodes harvested at 15 days with stimulators pulsed with 10 nM (Fig. 6A) and 1 μ M HY1 peptide (Fig. 6B). However, this distinction faded at 29d with KCSRNR-HY1 and ACSANA-HY1 priming for similar frequencies of HY1-specific CTLs in both lymph nodes and spleens. This similarity between ACSANA-HY1 and KCSRNR-HY1 continued through day 50 with comparable levels of priming. Testing at day 50 revealed a shift toward higher frequencies of HY1-specific CTLs in draining lymph nodes than spleens suggesting retention of the two polypeptides at the sites of injection through this timepoint with no consistent difference between ACSANA-HY1 and KCSRNR-HY1.

Example 5: MPL-AF is not required for increased immunogenicity by an immunogenic polypeptide. We investigated the possibility that MPL-AF is dispensable for MiHA polypeptides that are capable of efficiently precipitating CpG. B6 female mice were primed with the KCSRNR-HY1 immunogenic polypeptide + CpG (in our standard concentrations) with or without MPL-AF. The results of the ELISPOT assay for IFN γ -secreting CTLs demonstrated that the inclusion of MPL-AF in the priming mixtures did not increase the efficiency of stimulation of HY1-specific CTLs and that CpG was sufficient for priming with KCSRNR-HY1 (FIG. 7). In fact, the elimination of MPL-AF appeared to increase the efficiency of priming with only KCSRNR-HY1 and CpG.

Example 6: An immunogenic polypeptide increased immunogenicity of melanoma polypeptides. To determine if the addition of KCSRNR amino acid sequence could increase the immunogenicity of polypeptides other than HY1 and H60, a series of HLA-A2-binding

polypeptides with KCSRNR amino acid sequences was synthesized. The series included five polypeptides from the tyrosinase, gp100, and MelanA proteins that are specifically expressed by melanocytes and melanoma cells. Since these proteins are normally expressed in mice and humans, tolerance must be broken to achieve priming of CTLs. We also included the immunodominant influenza polypeptide (GILGFVFTL), which is a foreign protein for mice and humans. All of these bipartite polypeptides precipitated CpG whereas none of the native polypeptides precipitated CpG. Recipient mice were HLA-A2 transgenic mice that were selected on the B6 background (Le *et al.*, *J. Immunol.* 142:1366, 1989). Although these mice expressed HLA-A2 molecules on the cell surface with densities comparable to H2Db molecules, the frequency of influenza-specific CTLs that were restricted by HLA-A2 was drastically reduced in comparison to the frequency of influenza-specific CTLs that were restricted by H2Db (Le *et al.*, *J. Immunol.* 142:1366, 1989). Further, HLA-A2-restricted CTL responses to immunogenic polypeptides has been shown to be reduced in these transgenics (Engelhard *et al.*, *J. Immunol.* 146:1226, 1991) presumably due to the reduced binding of HLA-A2 molecules to mouse b2M and CD8. These mice, obtained from the Jackson Laboratory, had a reduced responsiveness to HLA-A2-restricted polypeptides. HLA-A2 transgenics were primed s.c. with mixtures of 100 μ g of CpG mixed with (1) 100 μ g of native polypeptides and (2) amounts of KCSRNR-containing polypeptide to yield equimolar CpG:peptide ratios. Spleens were harvested 10 days after immunization and CD8⁺ CTLs were purified by CD8⁺ Negative Selection Kits (Miltenyi Biotec, Auburn, CA) for use in primary IFN γ ELISPOT assays. Stimulators included T2 cells pulsed with titrated concentrations of native melanoma polypeptides. Non-pulsed T2 cells did not stimulate IFN γ production. The results of this assay demonstrated that the addition of a KCSRNR amino acid sequence resulted in increased priming for the influenza polypeptide and two of the melanoma-specific polypeptides, AAGIGILTV from MelanA and KTWGQYWQV from gp100 (FIG 8). The responses to KCSRNR-containing polypeptides were ~6-10 fold higher than the responses to the respective, natural polypeptides. Thus, with no modification to priming technique, we were able to boost the response of recipient mice with handicapped CTL responses to polypeptides presented by HLA-A2 molecules.

30

Example 7: An immunogenic bipartite HY1-Polypeptide precipitated CpG To confirm the presence of CpG in precipitates, HY1 and a series of immunogenic bipartite HY1 polypeptides were mixed with 100 μ g CpG at molar ratios of approximately 7:1. After 15 min incubation at room temperature, the mixtures were centrifuged at 1000 x g for 15 sec.

Optical densities (260/280nm) of diluted supernatants were measured after centrifugation to estimate the efficiency of precipitation of CpG (FIG. 9). These results confirmed that the KCSRNR-HY1 and KASRNR-HY1 polypeptides precipitated nearly all of the CpG in solution; the natural HY1 polypeptide precipitated ~30% of the CpG. These results support the hypothesis that the positively charged amino acids are important for precipitation of CpG and indicate that these concentrations of bipartite polypeptide and CpG result in the virtually complete conversion of free CpG to precipitated CpG.

To further investigate the precipitation that occurs when CpG is mixed with HY1-tailed polypeptides, experiments were designed to assess the roles of Arg/Lys and Cys residues in the polypeptide tail. HY1 bipartite polypeptides including KASRNR, ACSANA, and AASANA tails were used in the analysis. CpG oligonucleotides (6 nmol) were mixed in triplicate with the HY1 bipartite polypeptides (20 nmol) for 15 minutes at room temp. Precipitates were pelleted at 10,000 x g, and supernatants were diluted 1/100 for spectrometric analysis at 260 nm. As shown in FIG. 10, KASRNR-HY1 precipitated ~90% of soluble CpG, and ACSANA-HY1 and AASANA-HY1 had no significant effects on CpG levels. These results support the contention that the initially observed particulate precipitation is the function of interactions between the highly polar nucleic acids and the charged Arg/Lys amino acids of the primotope tails.

The presence of free peptides in mixtures of peptide plus CpG was quantitated by reverse phase-HPLC, but this method of analysis precluded detection of CpG oligonucleotides and potentially bound peptides. Two forms of CpG oligonucleotide were used in these experiments: (1) native CpG with phosphodiester linkages and (2) CpG with one phosphorothioate linkage between the fourth and fifth nucleotides (S1-CpG). The use of S1-CpG avoided the potential complexity of multiple bond formations. The mixture of AASANA-HY1 with S1-CpG resulted in the detection of the peptide as a single peak by RP-HPLC (FIG. 11A). Likewise, the ACSANA-HY1 signal was detectable following its mixture with native CpG (Figure 11B) but was undetectable following the mixture of ACSANA-HY1 with S1-CpG (FIG. 11C). The two sets of peaks in the ACSANA-HY1 + native CpG sample were presumed to represent monomers and dimers. These results suggested that the single Cys residue promoted binding of the ACSANA-HY1 bipartite polypeptide to S1-CpG and not native CpG. If this binding were due to disulfide bond formation between Cys-bearing peptides and S1-CpG, then reduction of the peptide:CpG mixture and alkylation of either of the components should eliminate binding. ACSANA-HY1 and S1-CpG were mixed and either analyzed directly by RP-HPLC or reduced with 50

mM dithiothreitol prior to analysis. As shown in FIG. 11D, reduction with dithiothreitol resulted in the release and detection of the ACSANA-HY1 primotope that was absent with the untreated mixture with S1-CpG (FIG. 11F). A single peak eluting as expected for a monomeric peptide was observed under these reducing conditions (FIG. 11D). Further,
5 alkylation of S1-CpG with iodoacetamide prior to admixture to ACSANA-HY1 eliminated binding as indicated by the detection of the putatively monomeric and dimeric ACSANA-HY1 primotopes (FIG. 11E). These results constitute strong evidence that sulfur-bearing CpG oligonucleotides and Cys-bearing polypeptides can form disulfide bonds that can be prevented by alkylation and reduction by dithiothreitol.

10

Example 8: Immunogenic polypeptide and CpG increased the efficiency of polypeptide absorption by Langerhans cells. The methods described herein can result in the direct precipitation of CpG by a bipartite, immunogenic, class I-binding polypeptide. The direct participation of both molecules in precipitation ensures that both will be present for the
15 duration of the precipitate and its deposit *in vivo*. Antigen-presenting cells (APCs) that take up the precipitate also receive CpG molecules for activation and class I-binding polypeptides for presentation to and recognition by CTLs. To test the uptake of the precipitate by APCs, KCSRNR-HY1 and the HY1 polypeptide were stained with Alexa 488, an amine-reactive dye, according to the manufacturer's protocol (Molecular Probes, Eugene, OR). CpG
20 molecules were stained with Texas Red maleimide through the use of a 5'EndTag Nucleic Acid Labeling System that utilizes T4 polynucleotide kinase (Vector Laboratories, Burlingame, CA). B10 mice were injected in the ears with a mixture of Alexa 488-polypeptide (10 µg/ear) and Texas Red-CpG (10ug/ear). Ears were injected with (A) KCSRNR-HY1 + CpG, or (B) HY1 + CpG. Ears were harvested at 12 hr, which is a time at
25 which Langerhans cells (LCs) have been shown to have been activated by local CpG injections (Jakob *et al.*, *J. Immunol.* 161:3042, 1998). Ears were split and LCs extracted by gentle treatment with 0.25% trypsin in Versene. The LC populations were viewed using an Olympus BX51 fluorescent microscope with a triple-pass filter for FITC (Alexa 488) and TRITC (red).

30

Images of cells revealed that in ears injected with HY1 + CpG, LCs absorbed both HY1 polypeptides and CpG molecules within 12 hr, but these molecules appeared to be concentrated within separate compartments in the LCs. In ears injected with KCSRNR-HY1 + CpG, the polypeptides and oligonucleotides were dispersed together throughout some of the LCs. Other LCs displayed concentrated CpG within restricted compartments as well as

dispersed polypeptides on the surface of cells. Thus precipitates of CpG and KCSRNR-HY1 can be taken up together by LCs with the subsequently effective and rapid (in comparison to HY1) transport of the polypeptides to the cell surface.

We also investigated the effects of Arg/Lys and Cys residues in tailed HY1 peptides on *in vivo* migration of Langerhans cells (LCs), which can present class I-bound peptides to CTLs. Activation of dendritic cells (DCs), including LCs, by CpG requires TLR9 expression and results in increased expression of cytokines and co-stimulatory molecules as well as migration to draining lymph nodes. To investigate the effect of the bipartite polypeptides on LC migration, B6 female mice (three per group) were injected in the hind footpads with Texas Red-stained CpG mixed with Alexa 488-conjugated HY1, KCSRNR-HY1, and ACSANA-HY1. Draining popliteal lymph nodes were harvested after 24 hr and lymphoid cells were dissociated to estimate the frequencies of doubly stained cells by fluorescent microscopy. The results presented in FIG. 12 indicate that the addition of KCSRNR and ACSANA tails increased the frequencies of doubly stained cells approximately 2.5-fold relative to the frequencies stimulated by HY1 peptide + CpG.

Example 9. Bipartite polypeptides increased efficiency of CpG uptake into macrophages. We also investigated the effects of bipartite polypeptides on the mechanisms of uptake of CpG by RAW-264 macrophages. CpG was end-labeled with Texas Red and mixed with the following bipartite polypeptides: AASANA-HY1, ACSANA-HY1, KASRNR-HY1, and KCSRNR-HY1. Texas Red-CpG was mixed with primotopes (5 μ g + 5 μ g) and the mixtures were diluted in growth medium for loading onto RAW cells on coverslips in a POC-R cell cultivation system (LaCon, Staig, Germany) mounted on a LSM 510 laser scanning confocal microscope (Carl Zeiss, Inc., Oberkochen, Germany). The POC-R chamber was heated to 37°C and the humidification system delivered a 5% CO₂/air mixture. Samples were excited with a 543 nm HeNe laser and viewed through a 63x/1.2 N.A. water C-Apochromat objective. Epi-fluorescence was collected through a 560-615 nm band pass filter with the pinhole set to 1 airy unit. Uptake was monitored over five minutes with data acquired at five second intervals. Differential Interface Contrast (DIC) images were collected with the transmitted light detector. Images of 512x512 were collected at 8-bit resolution, and data were analyzed with LSM Image Browser (Carl Zeiss) on a WindowsXP-based PC and with ImageJ (National Institute of Mental Health) on a Macintosh computer.

The bipartite polypeptides were clearly distinguished by their effects on the uptake of CpG. The slowest uptake was observed with AASANA-HY1 + CpG; CpG was taken up and

distributed throughout the cells. The most rapid uptake of CpG was driven by KASRNR-HY1. Upon addition of KASRNR + CpG, the cells immediately swelled and blebbed followed by the uptake of CpG that continually increased during the 5 min viewing period. Treatment with CpG mixed with ACSANA-HY1 and KCSRNR-HY1 resulted in uptake of CpG that was more rapid than with AASANA-HY1 and was concentrated in discrete cellular locations. This focused uptake was followed by pronounced movement of the cells that was only observed with these Cys-bearing primotopes + CpG. It was clear that the addition of Cys in KCSRNR-HY1 had blunted the rapid and apparently deleterious effects of the positively charged primotope. Importantly, the focused uptake of CpG observed with Cys-bearing primotopes correlated with the capacity to drive the increased CTL expansion.

Example 10: Known antigens have features of immunogenic polypeptides. The HY2 polypeptide, KCSRNRQYL, includes amino acids that are recognized by CTLs, control binding to H2Db molecules, mediate binding to CpG (Cys), and precipitate CpG (Arg and Lys). The combination of these characteristics can contribute to the relatively high immunogenicity of HY2 when administered with CpG. Further, the use of the first six amino acids (KCSRNR) of a bipartite HY1 and other polypeptides increases their immunogenicity when combined with CpG. These observations led us to examine the amino acid sequences of proteins that include a variety of immunogenic polypeptides and search for the presence of “natural immunogenic polypeptides” that include not only the recognition polypeptide but also flanking sequences that include Cys and positively charged residues that can bind to CpG. A precursory examination of known tumor, viral, and minor histocompatibility antigens revealed a remarkable tendency for class I-binding polypeptides to be flanked by multiple Arg and/or Lys residues. Table 1 illustrates such linkage in segments of three tumor-related proteins and one viral-encoded protein (class I-binding polypeptides in bold).

Table 1. Known antigens are flanked by Arg and/or Lys residues.

<i>Gene</i>	<i>Sequence</i>
HER-2/neu	IVSAVVGILLVVVLGVVFGIL KRRQ <u>KIRKY</u> TMRRLLQETELV*
MelanA	AAGIGILTVILGVLLIGCWY CR <u>RR</u> NGYR
PSA-1	FLTP KKLQ <u>CV</u> DLHVISNDV CAQV <u>HPQK</u> VT KF <u>MLCAGR</u> WTGGK
Adenovirus 3 (E3)	LIVIGILILSVILYFIF CR <u>QIPNVHR</u> NSKRR

*Residues in bold are class I-binding polypeptides; Arg, Cys, and Lys residues are underlined

Arg is selectively and sparsely used in proteins (Dyer, *J. Biol. Education* 5:15, 1971; King and Jukes, *Science* 164:788, 1969), an indication that the presence of Arg residues in flanking regions of class I-binding polypeptides may not be a random occurrence. The
5 observed regions of positively-charged amino acids are either a part of the polypeptides themselves or tend to be located up to 40 amino acids away from the polypeptide. We observed an apparent correlation between these positively charged segments that carry immunogenic polypeptides and genes whose functions depend on the functions of Arg residues. Proteins that functionally depend on Arg residues, such as DNA binding proteins
10 that must cross nuclear membranes and bind to DNA and members of the hydrophobic ABC transporter family, are highly represented as antigen sources. Continued analysis of known antigens further revealed that multiple immunogenic polypeptides can be found in clusters that share a linkage with a region of positively-charged amino acids. Thus, the membrane transport of one relatively large region has the potential to deliver more than one epitope
15 simultaneously.

OTHER EMBODIMENTS

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and
20 scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

WHAT IS CLAIMED IS:

1. A composition comprising a polypeptide and a CpG molecule, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue, and wherein said CpG molecule comprises at least one sulfur atom.
2. The composition of claim 1, wherein said CpG-interacting amino acid sequence further comprises at least one positively charged amino acid.
3. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises no more than 15 amino acid residues.
4. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises no more than 10 amino acid residues.
5. The composition of claim 1, wherein said CpG-interacting amino acid sequence consists essentially of 6 amino acid residues.
6. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises a B-X, X-B, or B-X-B sequence, wherein B is a positively charged amino acid residue and X is an amino acid residue.
7. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises an B-X-B-X-B sequence, wherein B is a positively charged amino acid residue and X is an amino acid residue.
8. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises at least two cysteine residues.

9. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises at least 4 positively charged amino acid residues.

5 10. The composition of claim 1, wherein at least one of said at least one cysteine residue of said CpG-interacting amino acid sequence is adjacent to a positively charged amino acid residue.

11. The composition of claim 10, wherein said CpG-interacting amino acid sequence
10 comprises the sequence set forth in SEQ ID NO:1 (KCSRNR).

12. The composition of claim 1, wherein said CpG-interacting amino acid sequence consists essentially of the sequence set forth in SEQ ID NO:1 (KCSRNR).

15 13. The composition of claim 1, wherein said CpG-interacting amino acid sequence consists essentially of the sequence set forth in SEQ ID NO:2 (ACSANA).

14. The composition of claim 13, wherein said at least one positively charged amino acid residue is an arginine.

20

15. The composition of claim 13, wherein said at least one positively charged amino acid residue is a lysine.

16. The composition of claim 1, wherein said cytotoxic T lymphocyte-activating
25 amino acid sequence comprises no more than 50 amino acid residues.

17. The composition of claim 1, wherein said cytotoxic T lymphocyte-activating amino acid sequence comprises no more than 25 amino acid residues.

30 18. The composition of claim 1, wherein said cytotoxic T lymphocyte-activating amino acid sequence comprises no more than 20 amino acid residues.

19. The composition of claim 1, wherein said cytotoxic T lymphocyte-activating amino acid sequence comprises no more than 10 amino acid residues.

5 20. The composition of claim 1, wherein said polypeptide is less than 50 amino acid residues in length.

21. The composition of claim 1, wherein said polypeptide is less than 40 amino acid residues in length.

10

22. The composition of claim 1, wherein said polypeptide is less than 30 amino acid residues in length.

23. The composition of claim 1, wherein said polypeptide is less than 20 amino acid
15 residues in length.

24. The composition of claim 1, wherein said CpG molecule comprises a phosphorothioate linkage.

20 25. The composition of claim 1, wherein said CpG molecule comprises a phosphorothioate backbone.

26. A method for producing a composition having enhanced immunogenicity, said method comprising:

25 (a) obtaining a polypeptide having a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, and wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue; and

30 (b) contacting said polypeptide to a CpG molecule comprising a sulfur atom to form said composition.

27. The method of claim 26, wherein said CpG-interacting amino acid sequence further comprises at least one positively charged amino acid.

5 28. A solution comprising a precipitate, wherein said precipitate comprises a polypeptide and a CpG molecule, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, wherein said CpG-interacting amino acid sequence
10 comprises at least one cysteine residue and at least one positively charged amino acid residue, and wherein said CpG molecule comprises a sulfur atom.

29. The solution of claim 28, wherein said solution is aqueous.

15 30. A method for making a solution comprising a precipitate, said method comprising:

 (a) obtaining a polypeptide having a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence,
20 and wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue and at least one positively charged amino acid residue; and

 (b) contacting said polypeptide to a CpG molecule comprising a sulfur atom, wherein said contacting is performed in solution and under conditions wherein said polypeptide and said CpG molecule form a precipitate, thereby forming said solution comprising a precipitate.
25

31. A method for activating a cytotoxic T lymphocyte within a mammal, said method comprising administering a composition comprising a polypeptide and a CpG molecule to said mammal, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T
30 lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino

acid sequence, wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue, and wherein said CpG molecule comprises a sulfur atom.

32. The method of claim 31, wherein said CpG-interacting amino acid sequence
5 further comprises at least one positively charged amino acid.

33. A method of identifying a polypeptide that activates cytotoxic T lymphocytes, said method comprising:

- (a) combining a test polypeptide with a CpG molecule to form a mixture;
- 10 (b) administering said mixture to a mammal;
- (c) harvesting cytotoxic T lymphocytes from said mammal; and
- (d) determining whether or not the level of CD8⁺ cytotoxic T lymphocytes in said mammal is increased compared to the level of CD8⁺ cytotoxic T lymphocytes in said mammal before step (b), wherein an increase indicates that said test polypeptide is said
15 polypeptide that activates cytotoxic T lymphocytes.

34. The method of claim 33, wherein said cytotoxic T lymphocytes are harvested from the spleen of said mammal.

20 35. The method of claim 33, wherein said mammal is a mouse.

36. A method of identifying a CpG-interacting amino acid sequence, said method comprising:

- (a) contacting a test amino acid sequence with a CpG molecule, wherein said
25 contacting is performed in solution, and
- (b) determining whether or not said test amino acid sequence and said CpG molecule form a precipitate, wherein the formation of a precipitate indicates that said test amino acid sequence is said CpG-interacting amino acid sequence.

30 37. A method of identifying a CpG-interacting amino acid sequence, said method comprising:

(a) administering a polypeptide/CpG molecule mixture to a mammal, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a test amino acid sequence, and

(b) determining whether or not said mixture activates cytotoxic T lymphocyte
5 from said mammal to a level greater than the level of activation that occurs in a control mammal that received a control polypeptide/CpG molecule mixture, wherein the polypeptide of said control polypeptide/CpG molecule mixture lacks said test amino acid sequence, and wherein said greater level of cytotoxic T lymphocyte activation indicates that said test amino acid sequence is said CpG-interacting amino acid sequence.

1/12

FIG. 1A





FIG. 1B






FIG. 2

3/12

FIG. 3A




FIG. 3B





FIG. 4



5/12

FIG. 5A





FIG. 5B



6/12

FIG. 6A






FIG. 6B




7/12

FIG. 7




8/12

FIG. 8



9/12

FIG. 9



10/12


FIG. 10

FIG. 11A




FIG. 11D




FIG. 11B




FIG. 11E




FIG. 11C






FIG. 11F



12/12

FIG. 12



(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 August 2005 (25.08.2005)

PCT

(10) International Publication Number
WO 2005/076975 A3

(51) International Patent Classification⁷: **A61K 39/00**,
39/385, 45/00, 47/00, C12Q 1/68

(21) International Application Number:
PCT/US2005/003754

(22) International Filing Date: 4 February 2005 (04.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/542,371 6 February 2004 (06.02.2004) US

(71) Applicant (for all designated States except US): **MAYO
FOUNDATION FOR MEDICAL EDUCATION AND
RESEARCH** [US/US]; 200 First Street S. W., Rochester,
MN 55905 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WETTSTEIN,
Peter, J.** [US/US]; 508 8th Avenue SW, Rochester, MN
55902 (US). **STRAUSBAUCH, Mike** [US/US]; 4404
8th Street N.W., Rochester, MN 55901 (US). **HARDIN,
Heather** [US/US]; 724 18th Avenue NE, Rochester, MN
55906 (US). **BORSON, Nancy** [US/US]; 415 15th Avenue
NE, Rochester, MN 55906 (US).

(74) Agent: **ELLINGER, Mark, S.**; Fish & Richardson P.C.,
P.A., 60 South Sixth Street, Suite 3300, Minneapolis, MN
55402-1104 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
10 November 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: COMPLEXED POLYPEPTIDE AND ADJUVANT FOR IMPROVED VACCINES

(57) Abstract: Attachment of the strongly immunogenic polypeptide to a more weakly immunogenic polypeptide can precipitate and focus a CpG adjuvant to increase *in vivo* priming of a cytotoxic T-lymphocyte (CTL) response, and thus increase the immunogenicity of the more weakly immunogenic polypeptide. Accordingly, compositions that include a bipartite immunogenic polypeptide are provided herein. The bipartite polypeptide can include a CpG-interacting amino acid sequence fused to a CTL-activating amino acid sequence that can be heterologous to the CpG-interacting amino acid sequence. Also provided are methods of identifying and using a CpG-interacting amino acid sequence and a bipartite immunogenic polypeptide.



WO 2005/076975 A3

INTERNATIONAL SEARCH REPORT

International appli

PCT/US05/03754

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 39/00, 39/385, 45/00, 47/00; C12Q 1/68 US CL : 424/185.1, 193.1, 278.1; 435/6 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/185.1, 193.1, 278.1; 435/6 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SCHIRMBECK et al. Antigenic Epitopes Fused to Cationic Peptide Bound to	1-6, 8-10, 16-32, 36
—	Oligonucleotides Facilitate Toll-Like Receptor 9-Dependent, but CD4+ T Cell Help-	
X	Independent, Priming of CD8+ T Cells. The Journal of Immunology. 2003, Vol. 171, pages 5198-5207, see entire reference.	33-35, 37
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B"	earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 07 July 2005 (07.07.2005)		Date of mailing of the international search report 26 AUG 2005
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Authorized officer Marianne DiBrino, Ph.D. <i>Christine Che</i> Telephone No. 571-272-1600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/03754

Continuation of B. FIELDS SEARCHED Item 3:

WEST 2.2.2, STN (EMBASE, BIOSIS, MEDLINE, CAPLUS, SCISEARCH, PROMT, BIOBUSINESS)

search terms: inventors' names, CpG, class I, adjuvant, cationic, fusion, epitope

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/037.

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 7 and 11-15
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims 7 and 11-13 recite sequence. Claims 14 and 15 depend upon claim 13. No CRF and paper copy of the sequence listing were furnished.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.